Our results suggest that individualized selection of chemotherapy combined with sequential immunotherapy according to BRCA1 mRNA expression level in the treatment of unresectable pancreatic cancer could control the disease and have controllable adverse reactions. This evidence concerns the gene BRCA1 and pancreatic neoplasm.